GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Graphite Bio Inc (NAS:GRPH) » Definitions » Price-to-Free-Cash-Flow

Graphite Bio (Graphite Bio) Price-to-Free-Cash-Flow : N/A (As of May. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Graphite Bio Price-to-Free-Cash-Flow?

As of today (2024-05-13), Graphite Bio's share price is $3.18. Graphite Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.37. Hence, Graphite Bio's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Graphite Bio's Price-to-Free-Cash-Flow or its related term are showing as below:

GRPH's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.985
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Graphite Bio's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-5.56. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-12.37.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -80.60% per year.

During the past 5 years, Graphite Bio's highest 3-Year average Free Cash Flow per Share Growth Rate was -80.60% per year. The lowest was -1002.60% per year. And the median was -541.60% per year.


Graphite Bio Price-to-Free-Cash-Flow Historical Data

The historical data trend for Graphite Bio's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graphite Bio Price-to-Free-Cash-Flow Chart

Graphite Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Graphite Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Graphite Bio's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Graphite Bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Graphite Bio's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Graphite Bio's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Graphite Bio's Price-to-Free-Cash-Flow falls into.



Graphite Bio Price-to-Free-Cash-Flow Calculation

Graphite Bio's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=3.18/-12.365
=N/A

Graphite Bio's Share Price of today is $3.18.
Graphite Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Graphite Bio  (NAS:GRPH) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Graphite Bio Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Graphite Bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Graphite Bio (Graphite Bio) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Executives
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Phil Gutry officer: CHIEF BUSINESS OFFICER 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Matthew Porteus director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Katherine V Stultz officer: CHIEF OPERATING OFFICER C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Abraham Bassan director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
L.p. 436, 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080